Erica J Brenner, Kimberly N Weaver, Xian Zhang, Arthur J Kastl, Jennifer A Strople, Jeremy Adler, Marla C Dubinsky, Athos Bousvaros, Runa Watkins, Xiangfeng Dai, Wenli Chen, Raymond K Cross, Peter D R Higgins, Ryan C Ungaro, Meenakshi Bewtra, Emanuelle A Bellaguarda, Francis A Farraye, Kelly Y Chun, Michael Zikry, Monique Bastidas, Ann Firestine, Riley G Craig, Margie E Boccieri, Millie D Long, Michael D Kappelman
BACKGROUND AND AIMS: COVID-19 vaccination prevents severe disease in most patients with inflammatory bowel disease (IBD), but immunosuppressive medications can blunt serologic response. We followed adults with IBD for >1 year post-COVID-19 vaccination to describe factors associated with SARS-CoV-2 infection after vaccination, evaluate for a protective SARS-CoV-2 antibody level, characterize SARS-CoV-2 antibody persistence, and identify factors associated with humoral immune response durability...
February 17, 2024: Clinical Gastroenterology and Hepatology